We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
-14.6%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$68.5B
AUM Growth
-$9.16B
Cap. Flow
+$4.06B
Cap. Flow %
5.93%
Top 10 Hldgs %
21.45%
Holding
3,375
New
359
Increased
2,434
Reduced
285
Closed
282

Top Buys

Rank Stock Value
1
LIN icon
Linde
LIN
+$124M
2
AAPL icon
Apple
AAPL
+$110M
3
MSFT icon
Microsoft
MSFT
+$104M
4
AMZN icon
Amazon
AMZN
+$71.3M
5
WBD icon
Warner Bros
WBD
+$69.6M

Top Sells

Rank Stock Value
1
T icon
AT&T
T
+$61.6M
2
CERN
Cerner Corp
CERN
+$50.9M
3
NXPI icon
NXP Semiconductors
NXPI
+$31.4M
4
AZPN
ASPEN TECHNOLOGY INC
AZPN
+$30.4M
5
YUMC icon
Yum China
YUMC
+$16.3M

Sector Composition

Rank Sector Weight
1 Technology 23.13%
2 Healthcare 14.42%
3 Financials 13.45%
4 Consumer Discretionary 10.49%
5 Industrials 9.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PLRX icon
3201
Pliant Therapeutics
PLRX
$65M
-22,867
Closed -$160K
PLSE icon
3202
Pulse Biosciences
PLSE
$2.62B
-13,340
Closed -$65K
PPTA
3203
Perpetua Resources
PPTA
$2.87B
-16,811
Closed -$69K
PRLD icon
3204
Prelude Therapeutics
PRLD
$362M
-10,050
Closed -$69K
PSNL icon
3205
Personalis
PSNL
$1.44B
-44,975
Closed -$368K
QMCO icon
3206
Quantum Corp
QMCO
$456M
-3,534
Closed -$160K
QNCX icon
3207
Quince Therapeutics
QNCX
$28.2M
-97
Closed -$120K
RCEL icon
3208
Avita Medical
RCEL
$138M
-22,913
Closed -$194K
REKR icon
3209
Rekor Systems
REKR
$88.2M
-34,677
Closed -$158K
RFL icon
3210
Rafael Holdings
RFL
$106M
-11,750
Closed -$29K
RGS icon
3211
Regis Corp
RGS
$68.6M
-2,051
Closed -$87K
RNAC icon
3212
Cartesian Therapeutics
RNAC
$245M
-3,618
Closed -$134K
RPID icon
3213
Rapid Micro Biosystems
RPID
$105M
-10,611
Closed -$72K
RRGB icon
3214
Red Robin
RRGB
$151M
-39,769
Closed -$671K
RVP icon
3215
Retractable Technologies
RVP
$20.1M
-15,372
Closed -$73K
RTB
3216
RTB Digital
RTB
$230M
-38
Closed -$56K
RYTM icon
3217
Rhythm Pharmaceuticals
RYTM
$7.59B
-56,942
Closed -$656K
SCOR icon
3218
Comscore
SCOR
$114M
-3,998
Closed -$233K
SLDB icon
3219
Solid Biosciences
SLDB
$859M
-4,777
Closed -$86K
SMMT icon
3220
Summit Therapeutics
SMMT
$10.8B
-15,115
Closed -$37K
SMSI icon
3221
Smith Micro Software
SMSI
$16M
-1,389
Closed -$209K
FTH
3222
Faeth Therapeutics
FTH
$634M
-808
Closed -$37K
SPRO icon
3223
Spero Therapeutics
SPRO
$73M
-24,740
Closed -$215K
SPRU icon
3224
Spruce Power Holding Corp
SPRU
$43.9M
-10,965
Closed -$175K
SPRY icon
3225
ARS Pharmaceuticals
SPRY
$532M
-24,075
Closed -$85K

Similar funds

RhumbLine Advisers's Q2 2022 Portfolio in Review

As of Q2 2022, RhumbLine Advisers held 3,375 positions worth $68.5B, down 12% from $77.7B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

RhumbLine Advisers deployed $4.06B of net new capital in Q2 2022, opening 359 new positions and adding to 2,434 existing holdings. Its largest new stake was Aspen Technology Inc: 81,883 shares worth $15M.

By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 25% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was AT&T, an estimated $61.6M trimmed.

  • RhumbLine Advisers's largest Q2 2022 buy was Aspen Technology Inc: 81,883 shares worth $15M.
  • RhumbLine Advisers added most to Linde in Q2 2022, an estimated $124M increase.
  • RhumbLine Advisers's biggest Q2 2022 reduction was AT&T, cutting an estimated $61.6M.
  • RhumbLine Advisers fully exited Cerner Corp in Q2 2022, selling an estimated $50.9M.
  • RhumbLine Advisers's ten largest holdings make up 21% of its $68.5B portfolio in Q2 2022.
  • RhumbLine Advisers opened 359 new positions and closed 282 in Q2 2022.
  • RhumbLine Advisers's portfolio value fell 12% quarter-over-quarter to $68.5B.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.